TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
ERAS

Erasca Inc

Healthcare · Biotechnology

14.80$ -3.7% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Erasca Inc (ERAS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 69.4% of the shares are freely tradable; institutional investors hold 93.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 93.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 10.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 69.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 9.9%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 350Mio.

Largest Shareholders

Institutions

Institutions ERAS
Name Stake (%) Shares Change (%) Date
Frazier Life Sciences Management, L.P. 7.05 24,675,188 +8.6 03/31/2026
T. Rowe Price Investment Management,Inc. 6.08 21,259,646 +1.7 03/31/2026
BlackRock Inc 5.76 20,151,406 +29.2 03/31/2026
VR Adviser, LLC 4.68 16,382,812 -8.3 03/31/2026
RTW INVESTMENTS, LLC 4.62 16,157,175 +10,917.4 03/31/2026
Logos Global Management LP 3.47 12,150,000 +9.0 06/30/2026
Vanguard Capital Management, LLC 3.22 11,249,738 +0.0 03/31/2026
Siren, L.L.C. 3.21 11,244,246 +28.4 03/31/2026
Paradigm Biocapital Advisors LP 2.73 9,550,000 -8.1 06/30/2026

Funds

Funds ERAS
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.81 9,814,143 +17.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?